MD 920

Drug Profile

MD 920

Alternative Names: MD 920G; MD-921

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aus Bio Limited
  • Class
  • Mechanism of Action Cell stimulants; Growth modulators; Nitric oxide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glaucoma; Wounds

Most Recent Events

  • 19 Apr 2010 Phase-I development is ongoing in Australia
  • 06 Jan 2005 Phase-I clinical trials in Wounds in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top